Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04514367 · ClinicalTrials.gov registry record · Phase 2
An Open Label Study of ANX005 in Subjects With, or at Risk for, Manifest Huntington's Disease
A Phase 2 study, sponsored by Annexon.
- Completed
- Registry status
- Phase 2
- Development phase
- 28
- Enrollment target
NCT04514367 is a Phase 2 study that has completed, run by Annexon. The registered enrollment target is 28 participants.
The verdict
NCT04514367, a Phase 2 study, has completed, sponsored by Annexon.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 28 participants
- Enrollment target
Study Summary
This study is a multi-center, open-label study of intravenous (IV) ANX005 in subjects with, or at risk for, manifest Huntington's Disease (HD).
Interventions
- DRUG ANX005
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2020-08-17 |
| Est. Completion | 2022-01-28 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04514367
The ClinicalTrials.gov registry entry for NCT04514367 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Annexon, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ANX005 is the first listed.
NCT04514367 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04514367 about?
NCT04514367 is a clinical study titled "An Open Label Study of ANX005 in Subjects With, or at Risk for, Manifest Huntington's Disease". This study is a multi-center, open-label study of intravenous (IV) ANX005 in subjects with, or at risk for, manifest Huntington's Disease (HD).
What is the current status of trial NCT04514367?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 28 participants. The study started on 2020-08-17. Estimated completion is 2022-01-28.
What interventions are being tested in trial NCT04514367?
The interventions under investigation include: ANX005 (DRUG).
Who is sponsoring clinical trial NCT04514367?
This trial is sponsored by Annexon, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.